Delivery Order SPE2DB25D3201-SPE2DB25FNVSR
- Not listed
- The Defense Logistics Agency awarded a $25,022.41 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Yervoy 200 mg/40 mL vials. The contract represents a firm fixed-price delivery against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply...
- The U.S. Department of Defense's Medical Supply Chain awarded a $22,957.99 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Yervoy 200 mg/40 mL vials. This competitive award, with an ultimate completion date of August 19, 2025, represents a firm fixed-price contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the delivery at its corporate office location. Yervoy (ipilimumab) is an immunotherapy...
- The Defense Logistics Agency awarded a delivery order valued at $11,435.46 to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Yervoy 50 mg/10 ml vials. This competitively awarded, firm fixed price delivery order is scheduled for completion by August 20, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA....
- The Defense Logistics Agency awarded a $114,789.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of YERVOY 200 mg/40 mL vials. This is a non-set-aside, competitively awarded contract with an ultimate completion date of August 28, 2025, and performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $36,457.87 to AmerisourceBergen Drug Corp for YERVOY (ipilimumab) 200 mg/40 mL vials. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 4, 2025. The contract was awarded on August 13, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Yervoy 50 mg/10 ml vial (10 ml), a prescription medication, with a ceiling value of $22,870.92. The contract is a firm fixed-price, non-set-aside award with a performance period ending on May 7, 2025. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The $11,185.38 firm fixed-price contract is for the supply of YERVOY 50 MG/10 ML VIAL 10ML, a specialty medication. The award has an ultimate completion date of January 2, 2025 and was made on December 10, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 between AmerisourceBergen and the DLA...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Yervoy 50 mg/10 ml vials, a medication used for the treatment of certain types of cancer. The contract has a firm fixed price and a ceiling value of $22,870.92. It is a non-set-aside contract, indicating open competition. The contract has an ultimate completion date of May 6, 2025 and was awarded on April...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corporation's Corporate Office Division. The $21,623.40 firm fixed-price delivery order is for the supply of 4566052958 Yervoy 50 mg/10 ml vials (10 ml). The contract has an ultimate completion date of October 30, 2024 and was awarded on October 8, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between DLA Troop Support Medical and...
- This is a $11,435.46 Firm Fixed Price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the supply of YERVOY 50 MG/10 ML VIAL 10ML, a pharmaceutical product, to support federal healthcare programs. The contract has an ultimate completion date of April 2, 2025 and was awarded on March 12, 2025. This delivery order is part of a larger $999,999,999 Indefinite Delivery...
- SPE2DB25D3201Indefinite Delivery Contract
- SPE2DB25D3201-SPE2DB25FNVSRDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Yervoy 50 mg/10 mL vials with a ceiling value of $11,435.46. This is a firm fixed price delivery order with an ultimate completion date of September 8, 2025, and no set-aside designation was utilized. The contract represents a competitive award under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The work will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Yervoy is a specialized immunotherapy pharmaceutical used in oncology treatments, reflecting the critical nature of medical supply procurement for military and federal healthcare systems. AmerisourceBergen Drug Corp, as a major pharmaceutical distributor and healthcare solutions provider, maintains a comprehensive portfolio of federal contracts supplying brand-name and generic medications, vaccines, and medical devices across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This delivery order exemplifies the company's role as a key vendor in the military medical supply chain and demonstrates the DLA's reliance on established prime vendors for specialized pharmaceutical products required to support military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.4k | 8/15/25 |